4

Univariate and multivariate survival analyses of the prognostic factors for overall and disease-free survival in EOC patients

Variablen Progression-free survivalOverall survival
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
Media of PFSPa HR95% CI For HRPb Media of OSPa HR95% CI For HRPb
Age (years)0.621NANANA0.676NANANA
 ≤511363042
 >51953144
Menopause0.373NANANA0.488NANANA
 Yes1543043
 No773244
Pathologic type0.978NANANA0.849NANANA
 Serous1163041
 Mucous and others*1153144
Histologic grade0.0251.0830.802–
1.462
0.6040.114NANANA
 G1–21414244
 G3903440
FIGO stage<0.0012.2651.632–
3.144
<0.001<0.0011.9941.423–
2.792
<0.001
 I–II814458
 III –IV1502439
LN metastasis0.0191.3660.958–
1.947
0.0850.0351.2740.887–
1.829
0.190
 No1863143
 Yes452441
Residual tumor (cm)0.277NANANA0.806NANANA
 <11873143
 ≥ 1443041
Ascites volume (mL)0.2370.403NANANA
 ≤100015740NANANA55
 >1000743658
Serum CA125 (U/mL)0.753NANANA0.991NANANA
 ≤6751403655
 >675913955
PVT1 expression0.0161.1110.819–
1.506
0.4980.0201.1530.842–
1.579
0.375
 Low1013451
 High1302840
MiR-214 expression0.0211.2460.925–
1.680
0.1480.0341.1930.880–
1.616
0.256
 Low1302841
 High1013144

Pa: P value, log rank test; HR: hazard ratio; CI: confidence interval; Pb: P value, Cox regression; CR: complete response; PR: partial response; SD: table disease; PD: progressive disease; NA: not applicable. *Others: others include the endometrioid, clear cell, and undifferentiated ovarian cancers.